HUE054037T2 - CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra - Google Patents

CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Info

Publication number: HUE054037T2
Authority: HU; Hungary
Prior art keywords: methods; activable antibody; conjugates against; active conjugates; active
Prior art date: 2017-10-14

Application number

HUE18797311A

Other languages

English (en)

Inventor

Shweta Singh

Jennifer Hope Richardson

Laura Patterson Serwer

Jonathan Alexander Terrett

Susan E Morgan-Lappe

Tracy Henriques

Sherry L Ralston

Marvin Robert Leanna

Ilaria Badagnani

Sahana Bose

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-14

Filing date

2018-10-12

Publication date

2021-08-30

2018-10-12 Application filed by Abbvie Inc filed Critical Abbvie Inc

2021-08-30 Publication of HUE054037T2 publication Critical patent/HUE054037T2/hu

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Cell Biology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HUE18797311A 2017-10-14 2018-10-12 CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra HUE054037T2 (hu)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762572467P	2017-10-14	2017-10-14

Publications (1)

Publication Number	Publication Date
HUE054037T2 true HUE054037T2 (hu)	2021-08-30

Family

ID=64110112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE18797311A HUE054037T2 (hu)	2017-10-14	2018-10-12	CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra

Country Status (36)

Country	Link
US (3)	US20190111150A1 (hu)
EP (2)	EP3834846A1 (hu)
JP (2)	JP7374891B2 (hu)
KR (4)	KR20230070046A (hu)
CN (1)	CN111278467B (hu)
AR (1)	AR115178A1 (hu)
AU (1)	AU2018346969A1 (hu)
BR (1)	BR112020007302B1 (hu)
CA (1)	CA3077730A1 (hu)
CL (1)	CL2020000977A1 (hu)
CO (1)	CO2020005685A2 (hu)
CR (1)	CR20200206A (hu)
CY (1)	CY1123968T1 (hu)
DK (1)	DK3691692T3 (hu)
DO (1)	DOP2023000150A (hu)
EC (1)	ECSP20025198A (hu)
ES (1)	ES2864013T3 (hu)
HR (1)	HRP20210436T8 (hu)
HU (1)	HUE054037T2 (hu)
IL (1)	IL273586A (hu)
LT (1)	LT3691692T (hu)
MA (1)	MA50752B1 (hu)
MD (1)	MD3691692T2 (hu)
MX (1)	MX2020003723A (hu)
PE (1)	PE20210125A1 (hu)
PH (1)	PH12020550417A1 (hu)
PL (1)	PL3691692T3 (hu)
PT (1)	PT3691692T (hu)
RS (1)	RS61596B1 (hu)
RU (2)	RU2022111211A (hu)
SG (1)	SG11202003378WA (hu)
SI (1)	SI3691692T1 (hu)
SM (1)	SMT202100184T1 (hu)
TW (2)	TW202330039A (hu)
UY (1)	UY37931A (hu)
WO (1)	WO2019075417A1 (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130116404A1 (en)	2011-11-08	2013-05-09	Case Western Reserve University	Targeted non-invasive imaging probes of egfr expressing cells
AU2016258628B2 (en) *	2015-05-04	2021-11-11	Cytomx Therapeutics, Inc	Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
IL271193B2 (en)	2017-06-07	2025-01-01	Regeneron Pharma	Preparations and methods for internalizing enzymes
WO2019183633A1 (en)	2018-03-23	2019-09-26	Case Western Reserve Univeristy	Psma targeted conjugate compounds and uses thereof
EP4132589A4 (en) *	2020-04-08	2024-05-08	Aliada Therapeutics, Inc.	COMPOSITIONS AND METHODS FOR DELIVERY OF THE BLOOD-BRAIN BARRIER
WO2021207657A1 (en) *	2020-04-09	2021-10-14	Cytomx Therapeutics, Inc.	Compositions containing activatable antibodies
EP4429654A1 (en)	2021-11-09	2024-09-18	Case Western Reserve University	Psma targeted conjugate compounds and uses thereof
WO2024026474A1 (en) *	2022-07-29	2024-02-01	Regeneron Pharmaceuticals, Inc.	Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3788058T2 (de)	1986-08-28	1994-04-21	Teijin Ltd	Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US5151510A (en)	1990-04-20	1992-09-29	Applied Biosystems, Inc.	Method of synethesizing sulfurized oligonucleotide analogs
NZ258392A (en)	1992-11-13	1997-09-22	Idec Pharma Corp	Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
WO2007027935A2 (en)	2005-08-31	2007-03-08	The Regents Of The University Of California	Cellular libraries of peptide sequences (clips) and methods of using the same
CA2697032C (en)	2007-08-22	2021-09-14	The Regents Of The University Of California	Activatable binding polypeptides and methods of identification and use thereof
KR101811965B1 (ko) *	2007-11-07	2017-12-22	셀덱스 쎄라퓨틱스, 인크.	인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
RU2636046C2 (ru)	2009-01-12	2017-11-17	Сайтомкс Терапьютикс, Инк	Композиции модифицированных антител, способы их получения и применения
CA2757638C (en) *	2009-04-29	2017-06-27	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Erg monoclonal antibodies
EP2427479B1 (en)	2009-05-07	2018-11-21	The Regents of The University of California	Antibodies and methods of use thereof
MX350200B (es) *	2011-02-01	2017-08-30	Genmab As	Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
TR201819828T4 (tr) *	2012-01-31	2019-01-21	Sbi Biotech Co Ltd	Anti-fosfolipaz d4 antikoru.
US9309510B2 (en)	2012-08-10	2016-04-12	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
CN103145847B (zh) *	2013-02-05	2014-05-21	浙江大学	一种抗cd20抗体-海兔毒素偶联物及其制备方法和应用
KR102535900B1 (ko) *	2013-12-25	2023-05-26	다이이찌 산쿄 가부시키가이샤	항 trop2 항체-약물 컨쥬게이트
AU2016258628B2 (en)	2015-05-04	2021-11-11	Cytomx Therapeutics, Inc	Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof
CN106237341B (zh) *	2016-07-12	2019-07-30	浙江大学	一种抗体偶联药物及其制备方法和应用

2018
- 2018-10-12 AU AU2018346969A patent/AU2018346969A1/en active Pending
- 2018-10-12 LT LTEP18797311.0T patent/LT3691692T/lt unknown
- 2018-10-12 UY UY0001037931A patent/UY37931A/es not_active Application Discontinuation
- 2018-10-12 PL PL18797311T patent/PL3691692T3/pl unknown
- 2018-10-12 CA CA3077730A patent/CA3077730A1/en active Pending
- 2018-10-12 PE PE2020000380A patent/PE20210125A1/es unknown
- 2018-10-12 HR HRP20210436TT patent/HRP20210436T8/hr unknown
- 2018-10-12 JP JP2020520804A patent/JP7374891B2/ja active Active
- 2018-10-12 MX MX2020003723A patent/MX2020003723A/es unknown
- 2018-10-12 RS RS20210341A patent/RS61596B1/sr unknown
- 2018-10-12 BR BR112020007302-4A patent/BR112020007302B1/pt active IP Right Grant
- 2018-10-12 AR ARP180102966A patent/AR115178A1/es not_active Application Discontinuation
- 2018-10-12 SG SG11202003378WA patent/SG11202003378WA/en unknown
- 2018-10-12 WO PCT/US2018/055733 patent/WO2019075417A1/en active Application Filing
- 2018-10-12 CR CR20200206A patent/CR20200206A/es unknown
- 2018-10-12 MD MDE20200822T patent/MD3691692T2/ro unknown
- 2018-10-12 KR KR1020237014403A patent/KR20230070046A/ko active Application Filing
- 2018-10-12 EP EP20209320.9A patent/EP3834846A1/en active Pending
- 2018-10-12 TW TW111137633A patent/TW202330039A/zh unknown
- 2018-10-12 US US16/159,559 patent/US20190111150A1/en not_active Abandoned
- 2018-10-12 SI SI201830233T patent/SI3691692T1/sl unknown
- 2018-10-12 RU RU2022111211A patent/RU2022111211A/ru unknown
- 2018-10-12 PH PH1/2020/550417A patent/PH12020550417A1/en unknown
- 2018-10-12 SM SM20210184T patent/SMT202100184T1/it unknown
- 2018-10-12 DK DK18797311.0T patent/DK3691692T3/da active
- 2018-10-12 TW TW107136020A patent/TWI780237B/zh active
- 2018-10-12 CN CN201880069577.4A patent/CN111278467B/zh active Active
- 2018-10-12 KR KR1020227044475A patent/KR102529359B1/ko active IP Right Grant
- 2018-10-12 PT PT187973110T patent/PT3691692T/pt unknown
- 2018-10-12 ES ES18797311T patent/ES2864013T3/es active Active
- 2018-10-12 HU HUE18797311A patent/HUE054037T2/hu unknown
- 2018-10-12 MA MA50752A patent/MA50752B1/fr unknown
- 2018-10-12 EP EP18797311.0A patent/EP3691692B8/en active Active
- 2018-10-12 KR KR1020207013706A patent/KR102385495B1/ko active Application Filing
- 2018-10-12 RU RU2020115713A patent/RU2771292C2/ru active
- 2018-10-12 KR KR1020227011264A patent/KR20220045088A/ko not_active Application Discontinuation
2020
- 2020-03-25 IL IL273586A patent/IL273586A/en unknown
- 2020-04-09 CL CL2020000977A patent/CL2020000977A1/es unknown
- 2020-05-07 CO CONC2020/0005685A patent/CO2020005685A2/es unknown
- 2020-05-13 EC ECSENADI202025198A patent/ECSP20025198A/es unknown
- 2020-11-25 US US17/105,402 patent/US20210145978A1/en not_active Abandoned
2021
- 2021-03-22 CY CY20211100239T patent/CY1123968T1/el unknown
2023
- 2023-05-19 US US18/320,869 patent/US20240115724A1/en active Pending
- 2023-07-27 DO DO2023000150A patent/DOP2023000150A/es unknown
- 2023-10-25 JP JP2023183034A patent/JP2024012366A/ja active Pending

Also Published As

Publication number	Publication date
JP2020537649A (ja)	2020-12-24
JP2024012366A (ja)	2024-01-30
TW201927815A (zh)	2019-07-16
JP7374891B2 (ja)	2023-11-07
TWI780237B (zh)	2022-10-11
KR20230070046A (ko)	2023-05-19
DK3691692T3 (da)	2021-03-22
MA50752A (fr)	2020-08-12
ECSP20025198A (es)	2020-06-30
MA50752B1 (fr)	2021-03-31
PT3691692T (pt)	2021-03-29
RU2022111211A (ru)	2022-05-05
BR112020007302A2 (pt)	2020-09-29
CY1123968T1 (el)	2022-05-27
HRP20210436T8 (hr)	2022-01-07
PH12020550417A1 (en)	2021-04-12
KR102385495B1 (ko)	2022-04-15
HRP20210436T1 (hr)	2021-04-30
ES2864013T3 (es)	2021-10-13
CL2020000977A1 (es)	2020-09-11
MD3691692T2 (ro)	2021-05-31
MX2020003723A (es)	2020-07-22
KR20230004932A (ko)	2023-01-06
KR20200070324A (ko)	2020-06-17
WO2019075417A1 (en)	2019-04-18
SI3691692T1 (sl)	2021-04-30
PE20210125A1 (es)	2021-01-19
EP3691692A1 (en)	2020-08-12
CA3077730A1 (en)	2019-04-18
US20210145978A1 (en)	2021-05-20
RU2020115713A (ru)	2021-11-16
US20240115724A1 (en)	2024-04-11
LT3691692T (lt)	2021-05-10
CO2020005685A2 (es)	2020-05-15
KR102529359B1 (ko)	2023-05-09
RU2771292C2 (ru)	2022-04-29
KR20220045088A (ko)	2022-04-12
AR115178A1 (es)	2020-12-09
CN111278467B (zh)	2024-07-30
EP3691692B1 (en)	2020-12-30
TW202330039A (zh)	2023-08-01
CN111278467A (zh)	2020-06-12
UY37931A (es)	2019-04-30
SG11202003378WA (en)	2020-05-28
US20190111150A1 (en)	2019-04-18
BR112020007302B1 (pt)	2023-01-31
DOP2023000150A (es)	2023-08-31
SMT202100184T1 (it)	2021-05-07
RS61596B1 (sr)	2021-04-29
CR20200206A (es)	2021-02-18
AU2018346969A1 (en)	2020-04-23
IL273586A (en)	2020-05-31
RU2020115713A3 (hu)	2022-02-25
EP3691692B8 (en)	2021-05-26
PL3691692T3 (pl)	2021-07-19
EP3834846A1 (en)	2021-06-16

Publication	Publication Date	Title
HUE054037T2 (hu)	2021-08-30	CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
IL265449A (en)	2019-05-30	Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
IL264654B1 (en)	2023-05-01	Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
SG11202003782XA (en)	2020-05-28	Triple-chain antibody, method for preparation and use thereof
ZA201806576B (en)	2020-01-29	Antibodies, pharmaceutical compositions and methods
HUE054103T2 (hu)	2021-08-30	Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
HUE053737T2 (hu)	2021-07-28	Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
HUE053332T2 (hu)	2021-06-28	Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
IL264161A (en)	2019-02-28	Tgfb antibodies, methods, and uses
LT3283521T (lt)	2023-12-27	Vaistų konjugatai, apimantys antikūnus prieš klaudiną 18.2
IL247659A0 (en)	2016-11-30	Antibodies against immunogenic glycopeptides, a preparation containing them and their use
HUE049081T2 (hu)	2020-09-28	GP120 elleni neutralizáló antitestek és alkalmazásuk
HUE053619T2 (hu)	2021-07-28	Anti-CD123 antitestek és konjugátumok és ezek származékai
EA201591750A1 (ru)	2016-05-31	Антитела против b7-h4 и иммуноконъюгаты
IL278877B1 (en)	2023-04-01	Amino-pyrazinecarboxamide compounds, conjugates and their uses
HUE059338T2 (hu)	2022-11-28	Ellenanyagok, alkalmazások és eljárások
EP3200823A4 (en)	2018-07-18	Multivalent meditopes, meditope-binding antibodies and uses thereof
DK3640207T3 (da)	2022-04-11	Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
DK3612579T3 (da)	2022-02-14	Pultrudat, fremstilling og anvendelse heraf
DK3265123T3 (da)	2023-01-30	Antistoffer, anvendelser og fremgangsmåder
EP3386460A4 (en)	2019-10-09	ORAL DEVICE, ARRANGEMENT AND METHOD FOR USE THEREOF
HK1254864A1 (zh)	2019-07-26	Hbed-二膦酸鹽/酯、其放射金屬軛合物和它們作為治療診斷劑的用途
HUE063621T2 (hu)	2024-01-28	ß-interferon elleni ellenanyagok és alkalmazásuk
GB201614162D0 (en)	2016-10-05	Antibodies, uses thereof and conjugates thereof
EP3620471A4 (en)	2021-01-06	ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE